Greedy Insider
Kura Oncology, Inc. (KURA) Insider Trades and Scores
Kura Oncology, Inc. (KURA) insider trades: since Dec 9, 2025, Greedy Insider recorded 2 open-market buys and 35 sales on Form 4 from 8 insiders. The strongest recent filing scored 91 (Strong).
Who bought and who sold
Across the last 37 scoreable Form 4 transactions in KURA, 2 were open-market purchases and 35 were sales. The table lists the most recent filings with each one's Greediness Score, so the structurally unusual trades are easy to spot first.
| Insider | Role | Type | Shares | Date | Score | ||
|---|---|---|---|---|---|---|---|
| Leoni Mollie | Chief Medical Officer | Sell | 28802.0 | 309566.78 | 2026-09-29 | 89 | View |
| FORD KATHLEEN | COO | Sell | 3668.0 | 39436.867 | 2026-09-29 | 86 | View |
| Powl Brian T. | Chief Commercial Officer | Sell | 15430.0 | 165852.44 | 2026-09-29 | 91 | View |
| Leoni Mollie | Chief Medical Officer | Sell | 12448.0 | 130670.39 | 2026-09-28 | 82 | View |
| DOYLE THOMAS JAMES | SVP, Finance & Accounting | Sell | 4607.0 | 48360.6 | 2026-09-28 | 84 | View |
| Bair Teresa Brophy | Chief Legal Officer | Sell | 8442.0 | 88618.2 | 2026-09-28 | 84 | View |
| FORD KATHLEEN | COO | Sell | 6906.0 | 72494.35 | 2026-09-28 | 90 | View |
| Powl Brian T. | Chief Commercial Officer | Sell | 9020.0 | 94685.65 | 2026-09-28 | 87 | View |
| Powl Brian T. | Chief Commercial Officer | Sell | 8000.0 | 84497.6 | 2026-09-28 | 86 | View |
| Burrows Francis | Chief Scientific Officer | Sell | 20726.0 | 224514.39 | 2026-09-24 | 87 | View |
The strongest recent filing
Powl Brian T. (Chief Commercial Officer) sold 15,430 shares of Kura Oncology, Inc. on Sep 29, 2026, a filing that scored 91 (Strong). It scored Strong because a senior insider was trading and several insiders moved the same way within a week. The score describes the filing, not future returns. This is not investment advice.
Cluster activity
A cluster buy is present: 6 insiders (Leoni Mollie, FORD KATHLEEN, Powl Brian T., DOYLE THOMAS JAMES) traded KURA the same direction within a 7-day window. Shared conviction is a stronger structural signal than a lone trade.
How this compares with Kura Oncology, Inc.'s own history
Open-market buys make up 5% of the 37 scoreable KURA transactions on record between Dec 9, 2025 and Sep 29, 2026. Comparing a filing with the company's own buy/sell mix is how you tell a routine disposal from an unusual accumulation.
Methodology and sources
Scores come from six published, user-adjustable factors (insider role, cluster activity, trade size versus the insider's own history, position impact, filing urgency, and direct versus indirect ownership). The score describes the filing, not future returns. This is not investment advice.
Key facts
- Scoreable Form 4 transactions on record: 37
- Open-market buys: 2
- Sales: 35
- Distinct insiders: 8
- Strongest recent Greediness Score: 91 (Strong)
Primary sources
Related
- Strongest filing
- KURA in the live feed
- How the Greediness Score works
- What is a cluster buy?
- Form 4 transaction codes
The score describes the filing, not future returns. This is not investment advice.